This is an old revision of this page, as edited by Violetriga (talk | contribs) at 14:39, 28 May 2018 (reporting). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 14:39, 28 May 2018 by Violetriga (talk | contribs) (reporting)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Young blood transfusion refers to transfusing blood specifically from a young person into an older one with the intention of creating a medicinal benefit. The scientific community currently views the practice as little more than snake oil.
Research
Research was done on rodents at Stanford University in which blood transfused from young mice seemed to invigorate older mice; the circulatory systems of the mice were connected which put them in a state of parabiosis. In experiments like this, researchers found that some of these mice died quickly (11 out of 69 in one experiment) for reasons the scientists could not explain, but described as possibly some form of rejection.
Evidence from two large studies in 2017 showed that the transfusion of blood from younger donors to older people was either no different from, or led to worse outcomes than, blood from older donors. Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; studies had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.
Commercial development
A startup company, Ambrosia, has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a clinical trial, to see if such transfusions lead to changes in the blood of recipients. The clinical trial has no control arm so is not randomized and is not blinded. The company was started by Jesse Karmazin, a medical school graduate without a license to practice medicine. David Wright is the licensed doctor overseeing the clinical trial; in his practice he gives intravenous treatments of vitamins and antibiotics for "non traditional" purposes, and was disciplined by the California Medical Board for the latter in 2015. A bioethicist from McGill suggests that Ambrosia is running this trial as they would be unable to get FDA approval to sell this treatment otherwise.
The company, Alkahest, was started based on the Stanford rodent studies, and as of 2017 was collaborating with European pharmaceutical company, Grifols, to create a blood plasma-based experimental biologic drug which they propose to test on people with Alzheimer's.
Reporting
Young blood transfusions have been called a "current trend" in regenerative medicine, with significant Silicon Valley investment in "life extension". Jeff Bercovici wrote for Inc. that it is "a popular obsession" and that there are rumours of wealthy technology bosses "spending tens of thousands of dollars for the procedures and young-person-blood". While media reports liken the potential to the Fountain of Youth and the elixir of life no evidence of success has been found in any human trial.
References
- ^ Novella, Steven (3 August 2016). "Parabiosis – The Next Snakeoil". Science-Based Medicine.
- Robbins, Rebecca. "Young-Blood Transfusions Are on the Menu at Society Gala". Scientific American. Retrieved 26 May 2018.
- ^ Garraud, O (August 2017). "Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?". Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 56 (4): 635–636. doi:10.1016/j.transci.2017.07.002. PMID 28780993.
- Ning, S; Heddle, NM; Acker, JP (January 2018). "Exploring donor and product factors and their impact on red cell post-transfusion outcomes". Transfusion medicine reviews. 32 (1): 28–35. doi:10.1016/j.tmrv.2017.07.006. PMID 28988603.
- ^ de Magalhães, JP; Stevens, M; Thornton, D (November 2017). "The Business of Anti-Aging Science". Trends in biotechnology. 35 (11): 1062–1073. doi:10.1016/j.tibtech.2017.07.004. PMID 28778607.
- Haynes, Gavin (21 August 2017). "Ambrosia: the startup harvesting the blood of the young". The Guardian. Retrieved 23 May 2018.
- ^ Maxmen, Amy. "This startup takes cash from aging adults in exchange for young people's blood". MIT Technology Review. Retrieved 26 May 2018.
- Drew, L (27 September 2017). "Neuroscience: The power of plasma". Nature. 549 (7673): S26 – S27. doi:10.1038/549S26a. PMID 28953857.
- ^ "Young Blood Transfusions - The Elixir Of Youth?". Medium. 1 November 2017. Retrieved 6 May 2018.
- Horn, Dara (25 January 2018). "The Men Who Want to Live Forever". The New York Times. Retrieved 25 May 2018.
- Bercovici, Jeff. "Peter Thiel Is Very, Very Interested In Young People's Blood". Inc. Retrieved 5 May 2018.
- Makin, Simon (21 April 2017). "Fountain of Youth? Young Blood Infusions "Rejuvenate" Old Mice". Scientific American. Retrieved 5 May 2018.